$NHPI !! Neuro-Hitech, Inc. is a specialty pha
Post# of 85277
(Total Views: 184)
Posted On: 10/05/2018 8:38:38 AM
$NHPI !! Neuro-Hitech, Inc. is a specialty pharmaceutical company focused on developing, marketing and distributing branded and generic pharmaceutical products primarily in the cough and cold markets. The Company’s principal business is operated through two subsidiaries: MCR American Pharmaceuticals (MCR) and AMBI Pharmaceuticals, Inc. (AMBI). The Company sells its products domestically through United States based distributors. In June 2008, the Company acquired MCR and AMBI. In January 2014, Neuro-Hitech Inc purchased two leases in Ft. Worth Basin in Texas.
MCR is focused on the acquisition, development, marketing and distribution of cough and cold, prenatal and pain management pharmaceutical products that provide quick and low-cost market entry through the ANDA, and OTC monograph regulatory approval pathways. MCR markets its products primarily to general practice, family practice, internal medicine, pediatric and ear, nose and throat (ENT) physicians. MCR provides physicians with offering of products within the cough, cold, allergy, mild pain management and pre-natal health areas. MCR’s branded pharmaceutical products include Maxiphen, Maxifed, Maxi-Tuss, Allfen, Promacet, Maxinate, Time-Hist and Ambifed. AMBI is focused on the distribution of generic equivalent pharmaceutical products to pharmaceutical wholesalers, distributors and chain pharmacies. AMBI has an account manager serving its customer base of distributors, wholesalers and retailers.
https://www.reuters.com/finance/stocks/compan...le/NHPI.PK
!! Revenue: $34.6 Million https://www.zoominfo.com/c/mcr-american-pharm...c/64521553
AMBI PHARM ~~>> annual revenue of $10 to 20 million and employs a staff of approximately 5 to 9. https://www.manta.com/c/mbnkf5w/ambi-pharmaceuticals-inc
MCR is focused on the acquisition, development, marketing and distribution of cough and cold, prenatal and pain management pharmaceutical products that provide quick and low-cost market entry through the ANDA, and OTC monograph regulatory approval pathways. MCR markets its products primarily to general practice, family practice, internal medicine, pediatric and ear, nose and throat (ENT) physicians. MCR provides physicians with offering of products within the cough, cold, allergy, mild pain management and pre-natal health areas. MCR’s branded pharmaceutical products include Maxiphen, Maxifed, Maxi-Tuss, Allfen, Promacet, Maxinate, Time-Hist and Ambifed. AMBI is focused on the distribution of generic equivalent pharmaceutical products to pharmaceutical wholesalers, distributors and chain pharmacies. AMBI has an account manager serving its customer base of distributors, wholesalers and retailers.
https://www.reuters.com/finance/stocks/compan...le/NHPI.PK
!! Revenue: $34.6 Million https://www.zoominfo.com/c/mcr-american-pharm...c/64521553
AMBI PHARM ~~>> annual revenue of $10 to 20 million and employs a staff of approximately 5 to 9. https://www.manta.com/c/mbnkf5w/ambi-pharmaceuticals-inc
(0)
(0)Scroll down for more posts ▼